Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations

Keri R. Maher, Andrew M Yeager

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Globoid cell leukodystrophy (GLD) is a progressive neurodegenerative disorder caused by the deficiency of galactocerebrosidase (GALC), resulting in accumulation of toxic metabolites in neural tissues. Clinically variable based on age of onset, infantile GLD is generally a rapidly fatal syndrome of progressive neurologic and cognitive decline, whereas later-onset GLD has a more indolent, protracted clinical course. Animal models, particularly the twitcher mouse, have allowed investigation of both the pathophysiology of and the potential treatment modalities for GLD. Cellular therapy for GLD, notably hematopoietic cell transplantation (HCT; transplantation of bone marrow, peripheral blood stem cells, or umbilical cord blood cells) from a normal related or unrelated allogeneic donor provides a self-renewing source of GALC in donor-derived cells. The only currently available treatment option in human GLD, allogeneic HCT, can slow the progression of the disease and improve survival, especially when performed in presymptomatic infants. Because persistent neurologic dysfunction still occurs after HCT in GLD, preclinical studies are evaluating combinations of HCT with other treatment modalities.

Original languageEnglish (US)
Pages (from-to)1180-1188
Number of pages9
JournalJournal of Neuroscience Research
Volume94
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Globoid Cell Leukodystrophy
Transplants
Therapeutics
Galactosylceramidase
Unrelated Donors
Poisons
Cell Transplantation
Neurologic Manifestations
Bone Marrow Transplantation
Fetal Blood
Age of Onset
Neurodegenerative Diseases
Nervous System
Disease Progression
Blood Cells
Animal Models
Tissue Donors

Keywords

  • galactocerebrosidase
  • GALC
  • globoid cell leukodystrophy
  • hematopoietic cell transplantation
  • Krabbe's disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Cellular transplant therapies for globoid cell leukodystrophy : Preclinical and clinical observations. / Maher, Keri R.; Yeager, Andrew M.

In: Journal of Neuroscience Research, Vol. 94, No. 11, 01.11.2016, p. 1180-1188.

Research output: Contribution to journalReview article

@article{2a13fa4077894593be701bed05ec40eb,
title = "Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations",
abstract = "Globoid cell leukodystrophy (GLD) is a progressive neurodegenerative disorder caused by the deficiency of galactocerebrosidase (GALC), resulting in accumulation of toxic metabolites in neural tissues. Clinically variable based on age of onset, infantile GLD is generally a rapidly fatal syndrome of progressive neurologic and cognitive decline, whereas later-onset GLD has a more indolent, protracted clinical course. Animal models, particularly the twitcher mouse, have allowed investigation of both the pathophysiology of and the potential treatment modalities for GLD. Cellular therapy for GLD, notably hematopoietic cell transplantation (HCT; transplantation of bone marrow, peripheral blood stem cells, or umbilical cord blood cells) from a normal related or unrelated allogeneic donor provides a self-renewing source of GALC in donor-derived cells. The only currently available treatment option in human GLD, allogeneic HCT, can slow the progression of the disease and improve survival, especially when performed in presymptomatic infants. Because persistent neurologic dysfunction still occurs after HCT in GLD, preclinical studies are evaluating combinations of HCT with other treatment modalities.",
keywords = "galactocerebrosidase, GALC, globoid cell leukodystrophy, hematopoietic cell transplantation, Krabbe's disease",
author = "Maher, {Keri R.} and Yeager, {Andrew M}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/jnr.23782",
language = "English (US)",
volume = "94",
pages = "1180--1188",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Cellular transplant therapies for globoid cell leukodystrophy

T2 - Preclinical and clinical observations

AU - Maher, Keri R.

AU - Yeager, Andrew M

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Globoid cell leukodystrophy (GLD) is a progressive neurodegenerative disorder caused by the deficiency of galactocerebrosidase (GALC), resulting in accumulation of toxic metabolites in neural tissues. Clinically variable based on age of onset, infantile GLD is generally a rapidly fatal syndrome of progressive neurologic and cognitive decline, whereas later-onset GLD has a more indolent, protracted clinical course. Animal models, particularly the twitcher mouse, have allowed investigation of both the pathophysiology of and the potential treatment modalities for GLD. Cellular therapy for GLD, notably hematopoietic cell transplantation (HCT; transplantation of bone marrow, peripheral blood stem cells, or umbilical cord blood cells) from a normal related or unrelated allogeneic donor provides a self-renewing source of GALC in donor-derived cells. The only currently available treatment option in human GLD, allogeneic HCT, can slow the progression of the disease and improve survival, especially when performed in presymptomatic infants. Because persistent neurologic dysfunction still occurs after HCT in GLD, preclinical studies are evaluating combinations of HCT with other treatment modalities.

AB - Globoid cell leukodystrophy (GLD) is a progressive neurodegenerative disorder caused by the deficiency of galactocerebrosidase (GALC), resulting in accumulation of toxic metabolites in neural tissues. Clinically variable based on age of onset, infantile GLD is generally a rapidly fatal syndrome of progressive neurologic and cognitive decline, whereas later-onset GLD has a more indolent, protracted clinical course. Animal models, particularly the twitcher mouse, have allowed investigation of both the pathophysiology of and the potential treatment modalities for GLD. Cellular therapy for GLD, notably hematopoietic cell transplantation (HCT; transplantation of bone marrow, peripheral blood stem cells, or umbilical cord blood cells) from a normal related or unrelated allogeneic donor provides a self-renewing source of GALC in donor-derived cells. The only currently available treatment option in human GLD, allogeneic HCT, can slow the progression of the disease and improve survival, especially when performed in presymptomatic infants. Because persistent neurologic dysfunction still occurs after HCT in GLD, preclinical studies are evaluating combinations of HCT with other treatment modalities.

KW - galactocerebrosidase

KW - GALC

KW - globoid cell leukodystrophy

KW - hematopoietic cell transplantation

KW - Krabbe's disease

UR - http://www.scopus.com/inward/record.url?scp=84990252375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990252375&partnerID=8YFLogxK

U2 - 10.1002/jnr.23782

DO - 10.1002/jnr.23782

M3 - Review article

C2 - 27638602

AN - SCOPUS:84990252375

VL - 94

SP - 1180

EP - 1188

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 11

ER -